We are pleased to welcome you to the summer 2016 edition of US Endocrinology, which as always includes the most timely and relevant information and opinion in the form of review articles and editorials written by key opinion leaders in the endocrinology arena.This edition includes a strong focus on obesity and diabetes. With the obesity epidemic come major challenges for endocrinologists, one of which is the quest to find a cure for diabetes. Many novel therapies are moving us towards this goal and, in this edition, Ilkowitz and Ranchandani review one of these: closed loop/artificial pancreas (CL/AP). Their timely review examines the evidence for the efficacy of this treatment based on the available data.
We also include several editorials from esteemed endocrinologists. Gonzalez-Campoy writes about the birth of bariatric endocrinology and future directions for obesity medicine. Lardinois highlights the importance of making the right nutritional recommendations to patients and Franz examines the role of weight loss in the management of type 2 diabetes. Also on this topic, Sellers writes about the high prevalence of type 2 diabetes among indigenous youth. Stein and Raal discuss PCSK9 inhibitors and Forlenza and Maahs examine the current diabetes therapies and technology that is available for the pediatric age group.
This edition also includes original research, on the topic of predictors of scalp hair thinning in women with polycystic ovary syndrome, from Ikhena et al. On the topic of thyroid cancer, Bauer et al. ask the question: how can we apply the new American Thyroid Association treatment guidelines for children and adolescents with thyroid cancer to improve patient management? And, in an editorial, Fridman et al. highlight their concerns with these guidelines. Finally, we have a case report by McAnich on a cutaneous false positive in radioiodine scintigraphy for metastatic thyroid cancer.
We do hope you enjoy this issue and welcome any feedback. Happy reading!